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ABSTRACT
The prevalence of diabetes is increasing due to
aging of the population and increasing obesity.
In the developed world, there is an
epidemiologic shift from diabetes being a
disease of middle age to being a disease of
older people due to increased life expectancy. In
old age, diabetes is associated with high
comorbidity burden and increased prevalence
of geriatric syndromes in addition to the
traditional vascular complications. Therefore,
comprehensive geriatric assessment should be
performed on initial diagnosis of diabetes. Due
to the heterogeneous nature of older people
with diabetes and variations in their functional
status, comorbidities, and life expectancy,
therapeutic interventions, and glycemic targets
should be individualized taking into
consideration patients’ preferences and putting
quality of life at the heart of their care plans.
Keywords: Diabetes mellitus; Geriatric
assessment; Glycemic targets; Older people;
Management; Type 2 diabetes
INTRODUCTION
With increasing aging of the population and
changes in lifestyle, the prevalence of diabetes is
likely to increase, especially among individuals
aged C75 years. Diabetes is associated with
premature morbidity, mortality, and is a
substantial health burden on individuals,
health systems, and society. Diabetes is the
seventh-leading cause of death in the US mainly
due to the increased cardiovascular risk [1].
However, in older people diabetes is a disabling
disease due to the traditionally associated
vascular complications, coexisting multiple
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comorbidities, and the increased prevalence of
geriatric syndromes, such as cognitive and
physical dysfunction, leading to increased risk
of nursing home admission by threefold [2].
Because of the complexity of diabetes in old age
and the heterogeneous nature of this age group,
comprehensive geriatric assessment is
important on the initial examination of older
people with diabetes with an individualized
goal of therapy aiming to prevent loss of
autonomy, and preserve independence and
quality of life. This article reviews the
management of type 2 diabetes in old age
with a focus on various aspects relevant to
older people.
METHODS
The authors performed a search of Medline and
Embase from January 1969 to March 2013 using
keywords relating to diabetes management in
older people. Only English language articles
were selected. Articles were reviewed for
relevance by abstract. A manual review of
citations in retrieved articles was performed in
addition to the electronic literature search. The
final list of cited references was chosen on the
basis of scientific quality and relevance to
the topic of review.
EPIDEMIOLOGY
The increasing prevalence of obesity and global
aging of the population implies that the
incidence and prevalence of diabetes will
continue to rise. The worldwide prevalence of
diabetes will double from the year 2000–2030,
with the greatest increase in those [65 years of
age [3]. In France between 2000 and 2009, the
prevalence increased with age to 14.2% in those
aged 65–74 years, peaking at 19.7% in men and
14.2% in women aged 75–79 years [4]. In the
US, total diabetes prevalence is estimated to be
14% of the population and is highest in those
aged C65 years, and by the year 2050 diabetes
prevalence could be as high as 33% [5].
However, the prevalence of undiagnosed
diabetes remains high. In the National Health
and Nutrition Examination Survey (NHANES),
the prevalence of diagnosed diabetes in those
C75 years old was 14.9%, and undiagnosed
diabetes based on fasting plasma glucose and
2-h oral glucose tolerance test was 13.4%. This
makes a total prevalence of diagnosed and
undiagnosed diabetes of 28.3%, and
undiagnosed diabetes constitutes a proportion
of approximately 47% [6]. In care homes
diabetes affects approximately 20–25% of
residents in the UK [7]. In the US
approximately 24.6% of nursing home
residents had diabetes in 2004 [8]. The trend
in prevalence increased from 1995 to 2004
(16.9–26.4% in males and 16.1–22.2% in
females, P\0.05) [9]. For the oldest residents
(aged C85 years), the prevalence increased from
13.1–19.5% in males (P = 0.02) and from
11.3–16.1% in females (P = 0.04) [9]. A more
recent survey showed a further increase in the
prevalence affecting approximately 32.8% of
residents [10].
ETIOLOGY
Normal glucose homeostasis requires both
normal insulin secretion by beta cells of the
pancreas and normal peripheral glucose
utilization by peripheral tissues sensitive to
insulin. In old age, increased adiposity and
decreased physical activity predispose older
people to develop insulin resistance [11]. As
the muscle tissue is the main site of glucose
consumption, the loss of muscle mass or
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sarcopenia associated with aging increases the
risk of developing insulin resistance, glucose
intolerance, and diabetes [12]. Aging is also
associated with impaired insulin secretion [13].
Therefore, in older people with diabetes
abnormalities in both insulin sensitivity and
insulin secretion underlie the development of
type 2 diabetes, which develops gradually, over
several years, as a result of progressive
deterioration of glucose control from normal
glucose tolerance to impaired glucose tolerance,
to clinically manifest diabetes. Both insulin
resistance and impaired insulin secretion
contribute to development of diabetes with a
principle defect of insulin secretion in lean
individuals and insulin resistance in obese ones.
Another factor is the diminished secretion of
incretin hormones in patients with type 2
diabetes. The incretin hormones normally
reduce blood glucose level by inducing
glucose-dependent insulin release and
inhibition of glucagon secretion.
CLINICAL PRESENTATION
Diabetes can be asymptomatic in up to 50% of
older people [14]. However, when symptoms are
present they are nonspecific and can be
attributed to aging. Nonspecific symptoms,
such as being generally unwell, fatigued, or
lethargic, are common manifestations of
diabetes in old age. Geriatric syndromes may
be the first manifestation of diabetes, such as
falls and urinary incontinence. Symptoms could
also be atypical, such as anorexia, rather than
the typical polyphagia. The classic osmotic
symptoms of diabetes are usually less
prominent due to the increased renal
threshold for glucose (reducing the intensity
of polyuria) and impairment of thirst sensation
(reducing the intensity of polydipsia). Diabetes
complications, such as non ketotic
hyperosmolar coma, may be the presenting
symptom or diabetes may be first diagnosed
during an acute illness or a routine blood test.
DIAGNOSIS
Diabetes is diagnosed if fasting plasma glucose
is C7 mmol/L or the 2-h postprandial glucose is
C11.1 mmol/L regardless of age [15]. However,
normal glycemia is defined as fasting plasma
glucose \6.1 mmol/L or 2-h postprandial
glucose \7.8 mmol/L. Therefore, the two
categories between normal glycemia and
diabetes are impaired fasting glycemia (fasting
glucose C6.1 but \7 mmol/L) and impaired
glucose tolerance (2-h post prandial glucose
C7.8 but \11.1 mmol/L). These two categories
are at high risk of developing diabetes and
vascular complications [16]. Clinicians should
be aware that older people may have normal
fasting glucose levels in the early stages of
diabetes. Fasting blood glucose is less sensitive
in diabetes diagnosis in old age but 2-h glucose
tolerance test appears to capture undiagnosed
cases [17]. Glycosylated hemoglobin (HbA1c)
can be used as a diagnostic test with a cut off
level of C48 mmol/mol (C6.5%) for diabetes
diagnosis. It has the advantage of convenience
to patients, less day-to-day variability,
specificity for diabetes, and it is standardized
internationally. However, although HbA1c has
high specificity (98.7%), its low sensitivity
(46.8%) means that it can miss more than half
of subjects with diabetes [18].
COMORBIDITY BURDEN
Chronic conditions are common among older
people with diabetes. Patients have at least one
comorbid chronic disease in addition to
Diabetes Ther (2013) 4:13–26 15
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diabetes and as many as 40% of patients have at
least three conditions [19]. The comorbidity
burden is even higher in care home residents
with diabetes. For example, patients have more
cardiovascular disease, visual problems, pressure
sores, limb amputations, and kidney failure
than residents without diabetes [20]. In a
retrospective case note review of 75 nursing
home residents with diabetes in the UK, very
significant levels of disability has been shown in
areas of continence, feeding, mobility, and
communication. Each individual had a mean
of four comorbidities (range 1–8) [21]. The
mortality rate reported from this study was
high (34%) after 1-year of follow-up, indicating
severe disability and frailty [22]. In another
study, residents with diabetes had a greater
comorbidity burden (Hierarchical Condition
Category 1.90 versus 1.58), more prescribed
medications, and experienced more
hospitalizations (37% versus 18%) than
residents without diabetes [10]. This increased
comorbidities in older people with diabetes
could be related to the improved survival and
decreased cardiovascular mortality [23].
GERIATRIC SYNDROMES
Geriatric syndromes, such as cognitive and
physical dysfunction, depression, and falls and
urinary incontinence, are common in older
people with diabetes and may have subtle
presentations [24]. Due to the effect of diabetes
on physical function the risk of disability in
performing activities of daily living is increased
by twofold compared to those without diabetes
[25]. Diabetes is also associated with reduced
muscle strength, poor muscle quality,
accelerated loss of lower extremity strength,
and muscle mass contributing further to
physical limitation and frailty [26]. Frailty can
be defined as a condition in which an older
person is coping just above the threshold of
disability; therefore, any physical or
psychological stress can lead to loss of
independence and overt disability [27].
Diabetes mellitus and insulin resistance
increase the likelihood of accelerated aging
process and development of frailty [28].
Diabetes complications may contribute to
worsening of geriatric syndromes, such as
increased risk of falls due to peripheral
neuropathy or impaired vision caused by
diabetic retinopathy. Unlike other chronic
conditions, diabetes care is dependent on the
patients’ ability to perform self-care tasks, which
may be compromised by both cognitive and
physical disability. For example, patients with
cognitive impairment may not be able to
recognize or treat hypoglycemia, or remember
and administer their insulin regime correctly.
Also, patients with depression may have problems
with medication or self-care compliance leading
to persistent hyperglycemia and increased risk of
diabetic complications [29].
GUIDELINES EVIDENCE
Guidelines for the management of diabetes in
old age do not have the same evidence-base as
those for younger diabetic populations due to
the exclusion of older people from clinical
trials.
Evidence for Glycemic Control
Tight glycemic control reduces microvascular
disease. However, the UK Prospective Diabetes
Study (UKPDS) is the only study that showed
benefit in reducing macrovascular disease [30].
The more recent randomized controlled trials
[31–33] have failed to show a benefit of tight
16 Diabetes Ther (2013) 4:13–26
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glycemic control in reducing macrovascular
complications, and mortality rate was
significantly higher in the intensive therapy
arm of the Action to Control Cardiovascular
Risk in Diabetes (ACCORD) trial (5% versus 4%)
[31]. The lack of benefit on macrovascular risk
reduction in these trials could be explained by
the relatively older population, longer duration
of diabetes, and the high prevalence of already
established cardiovascular disease (32–40%);
thus, minimizing the benefit of tight glycemic
control. On the other hand, the UKPDS
population was relatively younger and the
study had included only patients with newly
diagnosed diabetes and excluded those with
significant cardiovascular disease (Table 1
[30–33]).
Evidence for Older People
Currently, there is no evidence to suggest that
tight glycemic control will have a positive
impact on outcomes relevant to older people,
such as a delay in cognitive decline or disability
[34, 35]. In fact, low HbA1c \53 mmol/mol
(\7%) has been shown to increase risk of falls
[36]. In frail older patients, the presence of
competing comorbidities means that life
expectancy and quality of life may be reduced
more by other conditions than by diabetes. In a
decision analysis to assess the effects of baseline
health status on prioritization of intensive
control of glucose and blood pressure levels in
older patients with type 2 diabetes, intensive
blood pressure control conferred a larger benefit
than glucose control at advanced ages
(75–79 years old), and the expected benefits of
both therapies steadily declined as the level of
comorbid illness and functional impairment
increased [37]. Therefore, guidelines generally
recommend strict glucose control in healthier
older patients and lax approach in frail patients
with multiple comorbidities and high risk of
hypoglycemia [38].
MANAGEMENT
Diabetes management of older people should
take into account their heterogonous nature,
complex needs, and targets relevant to them
should be addressed at the outset considering
their goals and wishes, particularly quality of
life.
Initial Assessment
Older people with diabetes should have a
comprehensive geriatric assessment on
Table 1 Summary of recently published trials [30–33]
UKPDS ACCORD [31] ADVANCE [32] VADT [33]
Follow-up [30]
Number of patients 3,277 10,251 11,140 1,791
Mean (SD) age, years 62.0 (8) 62.2 (6.8) 66.0 (6) 60.5 (9)
Duration of diabetes on entry, years Newly diagnosed 10.0 8.0 11.5
Cardiovascular outcome Beneﬁt Harm No beneﬁt No beneﬁt
ACCORD Action to Control Cardiovascular Risk in Diabetes, ADVANCE Action in Diabetes and Vascular Disease:
Preterax and Diamicron MR Controlled Evaluation, UKPDS UK Prospective Diabetes Study, VADT Veterans Affairs
Diabetes Trial
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diagnosis. Geriatric syndromes, such as
cognitive and physical dysfunction, are
common complications of diabetes in old age
in addition to the traditional vascular
complications. Therefore, comprehensive
geriatric assessment should include screening
for microvascular complications, cardiovascular
risk factors, and geriatric syndromes (Table 2
[39]).
Life Style Modification and Drug Therapy
Healthy life style modifications, such as weight
reduction in overweight patients, regular
exercise, and smoking cessation, are similarly
beneficial in older people as they are in younger
people. Cardiovascular mortality risk remains
high even in older people ([75 years old)
with diabetes; therefore, cardiovascular risk
Table 2 Comprehensive geriatric assessment for older people with diabetes [39]
A. Microvascular complications
Retinopathy Screening for diabetic retinopathy as well as other ocular diseases common in older people, such as cataract,
glaucoma, and macular degeneration. Preservation of vision is important to prevent social isolation, reduce incidence of
falls, and maintain independence especially for self-medication with insulin
Nephropathy Chronic kidney disease is common in older people. Monitoring of renal function is essential for
adjustment of medications. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers should be used
in patients with persistent microalbuminuria
Neuropathy Regular feet inspection and access to diabetic foot care is essential in older people with diabetes as many
may not be able to care for their feet due to physical disability
B. Cardiovascular risk factors
Cardiovascular disease is the most common cause of mortality in patients with diabetes regardless of age. Life style
modiﬁcation, such as weight reduction, regular exercise, and smoking cessation, is recommended. Achieving blood
pressure and blood glucose control is essential along with dyslipidemia treatment and the use of antiplatelets as a
secondary prevention
C. Geriatric syndromes
Screening for the following geriatric syndromes should be addressed on the initial assessment:
Cognition: cognitive impairment should be suspected if difﬁculties in self-care develop
Physical function: mobility, gait, balance, and ability to perform activities of daily living
Nutrition: oral health, chewing, swallowing, and hydration
Depression: suspected if noncompliance with medication develops
Comorbidity burden
Polypharmacy: medication review to reduce medication burden
Pain: assessment for neuropathic and nonneuropathic pain
Urinary incontinence: could be the ﬁrst manifestation of diabetes
Social status: the need for help in self-care especially for those on insulin
18 Diabetes Ther (2013) 4:13–26
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reduction is recommended in those fit older
individuals as in younger people [40]. Special
considerations should be undertaken when
considering drug therapy in older people with
diabetes.
Metformin
Metformin is a good first-line therapy in older
people due to lower risk of hypoglycemia and
the potential weight loss in obese patients.
However, renal function should be carefully
monitored as chronic kidney disease is more
common with increasing age. Metformin
should be withdrawn if glomerular filtration
rate (GFR) drops \30 mL/min/1.73 m2.
The most common side effects are
gastrointestinal, such as nausea, diarrhea, and
abdominal pain, which generally occur earlier
in treatment; therefore, metformin should be
started at a lower dose to test for tolerability.
When other conditions common in older
people, such as cardiac failure, dehydration,
or acute illness, develop, metformin therapy
should be reviewed due to increased risk of
lactic acidosis.
Sulfonylureas
Sulfonylureas are reasonable either first-line, if
metformin is not tolerated, or add-on therapy.
Long-acting sulfonylureas, such as
chloropropamide and glibenclamide, should
not be used in older people due to risk of
hypoglycemia. Shorter-acting agents, such as
gliclazide or glipizide, are more suitable.
Hypoglycemic episodes should be closely
monitored in older people using sulfonylureas.
Weight gain is another side effect of
sulfonylurea but may be advantageous in frail
and underweight patients. Sulfonylureas are
metabolized in the liver; therefore, liver
function should be monitored regularly.
Pioglitazone
Pioglitazone is another option as first-line,
when metformin and sulfonylureas are not
tolerated, or add-on therapy to delay use of
insulin. The advantage of pioglitazone in older
people is that it can still be used if renal
function is impaired and has low risk of
hypoglycemia. The main side effects are fluid
retention; therefore, it is not suitable for
congestive cardiac failure patients with
volume overload, and the increased
incidence of fractures and possible bladder
cancer.
Meglitinides
Meglitinides are rapid onset and short-acting
insulin secretors. They have less hypoglycemic
effect but a lesser risk of hypoglycemia than
sulfonylureas, and have the advantage of
targeting postprandial blood glucose level.
They are suitable for older people with high
risk of hypoglycemia, especially those with
irregular eating patterns. Unlike nateglinide,
repaglinide is more effective and can be safely
used in patients with renal impairment.
Alpha-Glucosidase Inhibitors
Alpha-glucosidase inhibitors act by reducing
intestinal glucose absorption. They are weak
hypoglycemic agents but their low risk of
hypoglycemia makes them suitable as add-on
therapy for older people. Their common side
effects are flatulence and diarrhea, which may
limit their use.
Dipeptidyl Peptidase IV Inhibitors
Dipeptidyl peptidase IV inhibitors are
moderately effective as mono- or add-on
therapy. They are weight neutral and their
major advantage in elderly patients is the
absent risk of hypoglycemia; however, their
Diabetes Ther (2013) 4:13–26 19
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doses need to be adjusted according to renal
function.
Glucagon-like Peptide-1 Mimetics
Glucagon-like peptide-1 mimetics are injectable
drugs suitable as mono- or add-on therapy. The
main advantage in elderly patients is the absent
risk of hypoglycemia. They are also associated
with weight loss, which may be an advantage in
obese individuals. However, gastrointestinal
side effects are common and may be
associated with the increased incidence of
pancreatitis. They are also not suitable for frail
patients or those with GFR \30 mL/min/
1.73 m2.
Insulin
Insulin should be used in elderly patients when
drug therapy is not tolerated or insufficient to
achieve satisfactory glycemic control. The new
long-acting insulin analogs are suitable for older
people due to the ease of use and lower risk of
hypoglycemia. Older patients and their carers
should be adequately educated about symptoms
and treatment of hypoglycemia as well as blood
glucose monitoring before starting insulin
therapy.
Glycemic Targets
Due to heterogeneity of older people with
diabetes, glycemic targets should be
individualized taking into consideration the
individuals’ overall health and life expectancy.
Fit Older People
For healthier older people with low prevalence
of cardiovascular risk factors, especially those
with a new diagnosis of diabetes, tight glycemic
control with a HbA1c approximately 53 mmol/
mol (7%) is reasonable. The UKPDS follow-up
study showed the benefit of improved glycemic
control on lowering cardiovascular events in
newly diagnosed patients with diabetes and low
prevalence of cardiovascular disease [30].
Also, it has been shown that persistent
hyperglycemia is associated with the increased
risk of mortality [41] and falls [42] regardless of
the associated comorbidities.
Frail Older People
For frail older people or those with established
cardiovascular disease, a safer target
approximately 58–64 mmol/mol (7.5–8.0%) is
appropriate. The presence of multiple
comorbidities is a potential competitor for the
benefit of tight glycemic control in this
population. In a decision analysis to assess the
effects of comorbid conditions and functional
impairment, the expected benefits of tight
glycemic control (HbA1c 53 versus 63 mmol/
mol [7.0% versus 7.9%]), declined steadily as the
level of comorbidities and functional
impairment increased. For example, in patients
aged 60–64 years with new onset diabetes, the
quality-adjusted days declined from 106 (95%
confidence interval [CI]: 97, 117) days to 44
(range 38–50) days, with 3 additional points in
mortality index score and to 8 (range 5–10) days
with 7 additional index points [37].
Very Frail Older People
For very frail older people, and those residents
in nursing homes and with a limited life
expectancy, a target HbA1c of 64–75 mmol/
mol (8–9%) is appropriate. Tight glycemic
control in this population may be harmful by
inducing hypoglycemia and reducing quality of
life. Also, higher HbA1c[75 mmol/mol ([9.0%)
has been shown to be associated with increased
mortality [43]. Targets in this population should
focus on short-term day-to-day blood glucose
levels rather than a long-term HbA1c, due to
limited life expectancy, to avoid both
20 Diabetes Ther (2013) 4:13–26
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hyperglycemia, which may lead to lethargy,
dehydration, visual impairment, and infections
and hypoglycemia, which may lead to falls and
confusion (Fig. 1).
Considerations in Older People
Care Homes
Care home residents with diabetes are likely to
be frail, with multiple comorbidities and
limited life expectancy. Therefore, short-term
glycemic targets with minimal diabetes-related
interventions are more important to maintain
quality of life. Maintaining a random blood
glucose [4 but \15 mmol/L is a reasonable
target as blood glucose outside this range is
likely to be symptomatic and results in
cognitive changes [44]. Maintaining blood
glucose in this ‘‘comfort zone’’ may insure
‘‘comfort care’’ avoiding both hyperglycemia
Fig. 1 Diabetes diagnosis and management in older people.
*Atypical symptoms may include falls or generally unwell.
**Considerations, such as risk of hypoglycemia and
impaired cognitive function. FPG fasting plasma glucose,
HbA1c glycosylated hemoglobin, RPG random plasma
glucose, OGTT oral glucose tolerance test.
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and hypoglycemia, which may reduce malaise
and improve mental function and general
well-being [45]. Care homes should have a
policy for diabetes care, including diabetes
screening for residents on admission and
individualized care plans for residents.
Care plans should be tailored to patient
needs, which take into consideration patients’
values, preferences, their life expectancy,
comorbidities, and the impact of diabetes
management (polypharmacy, glucose
monitoring) on quality of life.
Dementia
Progressive decline in cognitive function leading
to dementia is common in older people with
diabetes. The relative risk of Alzheimer’s disease
is 1.5 (95% CI: 1.2, 1.8), and that of vascular
dementia is 2.5 (95% CI: 2.1, 3.0) [46]. The
increased prevalence of cardiovascular risk
factors, such as hypertension, dyslipidemia,
and hyperglycemia, could lead to increased
inflammation, oxidative stress and endothelial
dysfunction, and increased prevalence of
cerebrovascular disease, which may explain the
increased risk of vascular dementia with diabetes
[47]. On the other hand, insulin dysregulation,
protein glycation, amyloid deposition, and
direct cerebral glucose toxicity may lead to
accelerated brain aging, which may explain the
increased risk of Alzheimer’s disease in older
people with diabetes [48]. Although there is an
association between hyperglycemia and
cognitive dysfunction, it has been shown that
tight glycemic control was not able to prevent a
decline in mental function [34]. Older people
with diabetes and dementia experience
difficulties in performing self-care tasks. It has
been shown that once dementia develops
diabetes self-care (taking diabetes medication,
regular exercise, following a recommended
eating plan, blood glucose monitoring, and feet
inspection) deteriorates [49]. Patients are also
more likely to experience treatment-related
complications, such as severe hypoglycemia,
requiring assistance [50]. This is important as it
may alert the clinicians to screen for cognitive
dysfunction if patients’ noncompliance with
self-care task is observed or recurrent
unexplained hypoglycemia occurs. Clinicians
should also be aware that dementia may be
associated with language impairment,
disorientation, and personality changes, which
may mimic the symptoms of hypoglycemia [51].
Older people with diabetes and dementia will
have complex needs due to increased
dependency and unpredictable behavioral
changes as the decline in cognitive function
continues. For example, hydration should be
maintained due to impaired thirst sensation
to avoid risk of volume depletion and
hyperglycemic crises. In insulin-treated
patients, the new class of long-acting insulin
analogs may be a good option as they reduce the
risk of hypoglycemia and can be conveniently
injected once-daily [52]. Patients who have
erratic eating patterns and unpredictable caloric
intake could be managed with a regime where
short-acting insulin analogs are administered
only after meal consumption; thus, preventing
insulin-induced hypoglycemia if a meal is missed
or only partly consumed.
Hypoglycemia
Older people with diabetes are at increased risk
of hypoglycemia even at a comparable glycemic
control to younger people due to the associated
multiple comorbidities [53, 54]. Older patients
may tolerate low blood glucose with no specific
symptoms due to diminished autonomic
response with old age. Therefore, it is
important that patients and carers are educated
to recognize the symptoms and to treat
hypoglycemia. Educational programs should be
22 Diabetes Ther (2013) 4:13–26
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adapted to patients’ and carers’ abilities.
Medications should be reviewed to switch
patients taking longer-acting sulfonylureas into
shorter-acting agents and polypharmacy
reviewed regularly.
Quality of Life
Quality of life should be maintained without
subjecting frail older people to unnecessary
therapeutic interventions. Tight glycemic
control, including dietary restriction, frequent
blood testing, insulin injections, and
polypharmacy, may be a burden leading to
additional complications. For example, dietary
restriction may cause weight loss, frequent
finger sticks and insulin injections may lead to
agitation especially in patients with dementia,
and polypharmacy increasing risk of falls.
Holistic Approach
Due to the heterogeneity of older people with
diabetes, individualized and a holistic care plan
is recommended to address their complex
needs, taking into consideration their wishes
and preferences, their functional status, and life
expectancy with quality of life as the main
target.
Nutrition
Nutritional guidelines should not be too
restrictive but tailored to be healthy and to
reflect personal preferences. Individuals are free
to exercise personal choice with respect to food
selection. Diabetes treatment is then adjusted
accordingly. The aims of nutritional choices for
elderly diabetics include: (1) maintenance of
healthy body weight and avoidance of
malnutrition; (2) coordinated nutritional
needs with glycemic targets and adjustment of
diabetes medication, especially if food intake is
variable; (3) maintenance of hydration.
CONCLUSION
Prevalence of diabetes is increasing and aging of
population is the main driving factor. Older
people with diabetes tend to have multiple
comorbidities and develop geriatric syndromes
in addition to the traditional cardiovascular
complications. Therefore, initial assessment on
diagnosis should be comprehensive and include
screening for these syndromes, especially
cognitive and physical dysfunction. Due to the
heterogeneous nature of older people with
diabetes, management plans should be
individualized with variable glycemic targets
from tight control in fit individuals to lax
approach in frail ones. Quality of life should
be at the center of management plans.
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